Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
Public ClinicalTrials.gov record NCT02383940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX4211 in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
Study identification
- NCT ID
- NCT02383940
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Interventions
- Sotagliflozin Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 30 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2015
- Primary completion
- Aug 31, 2016
- Completion
- Aug 31, 2016
- Last update posted
- Feb 11, 2020
2015 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lexicon Investigational Site | Tustin | California | 92780 | — |
| Lexicon Investigational Site | Aurora | Colorado | 80045 | — |
| Lexicon Investigational Site | New Haven | Connecticut | 06519 | — |
| Lexicon Investigational Site | Tampa | Florida | 33612 | — |
| Lexicon Investigational Site | West Palm Beach | Florida | 33401 | — |
| Lexicon Investigational Site | Atlanta | Georgia | 30318 | — |
| Lexicon Investigational Site | Roswell | Georgia | 30076 | — |
| Lexicon Investigational Site | Indianapolis | Indiana | 46202 | — |
| Lexicon Investigational Site | New Orleans | Louisiana | 70121 | — |
| Lexicon Investigational Site | Auburn | Maine | 04210 | — |
| Lexicon Investigational Site | Boston | Massachusetts | 02215 | — |
| Lexicon Investigational Site | Buffalo | New York | 14222 | — |
| Lexicon Investigational Site | Wilmington | North Carolina | 28401 | — |
| Lexicon Investigational Site | Austin | Texas | 78749 | — |
| Lexicon Investigational Site | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02383940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02383940 live on ClinicalTrials.gov.